Attorney General Aaron M. Frey announced a settlement agreement with Sanofi-Aventis U.S. LLC after scrutiny over the ...

More than three years after approving two biosimilars referencing Sanofi’s long-acting insulin Lantus, the FDA has signed off on a rapid-acting insulin biosimilar for the first time. The agency ...

There is good news for Mainers who rely on insulin according to our media partners WMTW. Maine Attorney General Aaron Frey ...

Sanofi has announced it is going to invest €44 million on its site in Waterford, Ireland, in order to boost production of its top-selling insulin, Lantus. The Waterford site is currently the ...

In 2023, Sanofi jumped the bandwagon with the other two insulin U.S. giants to lower the price of its best-selling insulin product, Lantus (insulin glargine), by 78%. Sanofi said it would cap a ...

Sanofi's rivals in the insulin field are nipping at its heels – Lantus sales dipped 5 per cent in the first half of 2015, and analysts don't expect Toujeo to make up for its decline.

GoodRx said in a statement that it is working with Sanofi to offer U.S. insulin patients a coupon for to a 30-day supply of Lantus, an insulin glargine injection and Sanofi's most widely ...

Who Are the Key Players in the Lantus Market? The Lantus market features several major pharmaceutical companies, with Sanofi S.A. being a leading player. Industry giants like Sanofi contribute to ...

On average, insulin glargine biosimilars achieve a 26% market share after 5 years on the market. 3 Sanofi's dual pricing strategy may have slowed the market uptake of insulin biosimilars ...